Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio Holdings Inc (TVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 232,080
  • Shares Outstanding, K 170,647
  • Annual Sales, $ 0 K
  • Annual Income, $ -70 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta -1.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +34.65%
on 11/08/24
3.0900 -55.99%
on 10/25/24
-0.3600 (-20.93%)
since 10/18/24
3-Month
0.2556 +432.08%
on 10/09/24
3.0900 -55.99%
on 10/25/24
+0.7100 (+109.23%)
since 08/19/24
52-Week
0.2556 +432.08%
on 10/09/24
21.0900 -93.55%
on 02/15/24
-9.6000 (-87.59%)
since 11/15/23

Most Recent Stories

More News
Tevogen Bio Reports Significant Reduction in Net Loss and Dramatic Improvement in Financial Position for Q3 2024

Tevogen Bio reported a reduced net loss and improved financial position, eliminating most liabilities and retaining substantial equity among officers.Quiver AI SummaryTevogen Bio announced its financial...

TVGN : 1.3600 (+2.26%)
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Highlights Sustainable Growth and Strategic Financing in Upcoming Quarterly Financial Report

Tevogen Bio reports progress in developing immunotherapy, maintaining low expenditures and focusing on sustainable growth while preserving shareholder value.Quiver AI SummaryTevogen Bio, a clinical-stage...

TVGN : 1.3600 (+2.26%)
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)

Business Summary

Semper Paratus entered in definitive agreement for a business combination with Tevogen Bio Inc.

See More

Key Turning Points

3rd Resistance Point 1.5267
2nd Resistance Point 1.4533
1st Resistance Point 1.4067
Last Price 1.3600
1st Support Level 1.2867
2nd Support Level 1.2133
3rd Support Level 1.1667

See More

52-Week High 21.0900
Fibonacci 61.8% 13.1313
Fibonacci 50% 10.6728
Fibonacci 38.2% 8.2143
Last Price 1.3600
52-Week Low 0.2556

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar